Iqvia Holdings Inc. (NYSE: IQV)

Sector: Healthcare Industry: Diagnostics & Research CIK: 0001478242
P/B 6.31
P/E 30.28
P/S 2.44
Market Cap 38.85 Bn
ROIC (Qtr) 8.28
Div Yield % 0.00
Rev 1y % (Qtr) 5.24
Total Debt (Qtr) 15.19 Bn
Debt/Equity (Qtr) 2.47

About

IQVIA Holdings Inc., often recognized by its stock symbol IQV, operates in the life sciences industry, providing advanced analytics, technology solutions, and clinical research services. With a presence in over 100 countries and approximately 87,000 employees, IQVIA creates intelligent connections across all aspects of healthcare. The company's analytics, transformative technology, big data resources, extensive domain expertise, and network of partners enable life sciences companies to make critical decisions and perform better. IQVIA's main business...

Read more

Stock Price Chart

Analysis

Pros

  • Operating cash flow of 2.80B provides strong 11.93x coverage of stock compensation 235M, indicating sustainable incentive practices.
  • Operating cash flow of 2.80B provides exceptional 2804x coverage of minority interest expenses 1M, showing strong core operations.
  • Robust free cash flow of 2.29B exceeds capital expenditure of 518M by 4.41x, indicating strong organic growth funding capability.
  • Cash position of 1.81B provides exceptional 1814x coverage of minority interest expenses 1M, indicating strong liquidity.
  • Operating cash flow of 2.80B provides strong 2.32x coverage of operating expenses 1.21B, showing operational efficiency.

Cons

  • Operating cash flow of 2.80B barely covers its investment activities of (1.51B), with a coverage ratio of -1.86, indicating heavy reliance on external financing for growth which may not be sustainable in a tighter credit environment.
  • Cash reserves of 1.81B provide limited coverage of acquisition spending of (976M), which is -1.86x, suggesting aggressive expansion might strain liquidity if market conditions deteriorate.
  • Operating cash flow of 2.80B provides insufficient coverage of deferred revenue obligations of 2.16B, which is 1.30x, raising concerns about future service delivery capabilities.
  • Operating earnings of 2.29B show weak coverage of depreciation charges of 1.13B, with a 2.03 ratio indicating high capital intensity and potential reinvestment needs.
  • High depreciation of 1.13B relative to operating cash flow of 2.80B, which is 0.40x suggests significant maintenance capital requirements affecting free cash flow.

Peer Comparison

Companies in the Diagnostics & Research
S.No. Ticker Company Market Cap P/E P/S Total Debt (Qtr)
1 TMO Thermo Fisher Scientific Inc. 216.83 Bn 33.00 4.96 35.68 Bn
2 DHR Danaher Corp /De/ 162.47 Bn 46.38 6.69 16.86 Bn
3 IDXX Idexx Laboratories Inc /De 56.88 Bn 55.36 13.65 1.09 Bn
4 A Agilent Technologies, Inc. 39.82 Bn 32.64 5.87 3.41 Bn
5 IQV Iqvia Holdings Inc. 38.85 Bn 30.28 2.44 15.19 Bn
6 NTRA Natera, Inc. 31.32 Bn -101.29 14.80 0.18 Bn
7 MTD Mettler Toledo International Inc/ 28.99 Bn 34.68 7.35 2.21 Bn
8 WAT Waters Corp /De/ 22.92 Bn 35.32 7.38 1.49 Bn

Industry Comparisons

Current Valuation

Metric Value Industry Percentile
EV to Assets 1.83 2.69
EV to Cash from Ops. 18.73 18.14
EV to Debt 3.46 52.51
EV to EBIT 22.88 19.22
EV to EBITDA 15.86 4.35
EV to Free Cash Flow [EV/FCF] 22.97 2.84
EV to Market Cap 1.35 1.52
EV to Revenue 3.30 4.79
Price to Book Value [P/B] 6.31 1.34
Price to Earnings [P/E] 30.28 22.02

Dividend Metrics

Metric Value Industry Percentile
Dividend Coverage Ratio 0.00 -1.96
Dividend Payout Ratio % 0.00 2.83
Dividend per Basic Share 0.00 0.19
FCF Dividend Payout Ratio % 0.00 1.92
Interest Coverage 3.25 -126.58

Growth Metrics

Metric Value Industry Percentile
Capex Growth (1y) % 12.50 -31.50
Cash and Equivalents Growth (1y) % 15.39 21.37
Dividend Growth (1y) % 0.00 0.24
EBIAT Growth (1y) % -9.35 -55.24
EBITDA Growth (1y) % 3.34 -447.96
EBIT Growth (1y) % 5.66 -40.50
EBT Growth (1y) % 6.43 -70.94
EPS Growth (1y) % -4.80 -70.02
FCF Growth (1y) % 15.11 56.33
Gross Profit Growth (1y) % -0.28 185.11

Liquidity Ratios

Metric Value Industry Percentile
Asset Utilization Ratio 0.55 0.56
Cash Payout Ratio 0.00 0.01
Cash Ratio 0.21 1.21
Current Ratio 0.70 2.64
Debt to Equity Ratio 2.47 -0.80
Interest Cover Ratio 3.25 -126.58
Times Interest Earned 3.25 -126.58

Profitability

Metric Value Industry Percentile
EBITDA Margin % 21.50 -129.91
EBIT Margin % 14.43 -156.71
EBT Margin % 9.98 -162.23
Gross Margin % 33.80 47.70
Net Profit Margin % 8.10 -189.30